[{"to": "97", "prefix": "ased on in vitro rat and human hepatocyte uptake studies showing inhibition of ", "from": "90", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " uptake in the presence of the non-specific organic anion transporting polypepti"}, {"to": "367", "prefix": " single-dose, two-period, crossover design, subjects received a 7.5 mg dose of ", "from": "360", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone or immediately following a 600 mg intravenous dose of rifampin. Rifampin "}, {"to": "492", "prefix": "mg intravenous dose of rifampin. Rifampin did not significantly alter R- or S- ", "from": "485", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " area under the concentration-time curve (AUC) from 0–12 hours (period of hepati"}, {"to": "734", "prefix": "–∞ was decreased on rifampin days for both R- (25% reduction; p < 0.001) and S-", "from": "727", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (15% reduction; p < 0.05). No differences were seen on the area under the INR-t"}, {"to": "936", "prefix": "ic uptake via OATPs may not be clinically important in the pharmacokinetics of ", "from": "929", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ".\n\nKeywords: warfarin, pharmacokinetics, drug transporters, drug interaction, he"}, {"to": "957", "prefix": "ay not be clinically important in the pharmacokinetics of warfarin.\n\nKeywords: ", "from": "950", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", pharmacokinetics, drug transporters, drug interaction, healthy volunteers\nGo t"}, {"to": "1061", "prefix": "s, drug transporters, drug interaction, healthy volunteers\nGo to:\nINTRODUCTION\n", "from": "1054", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "Warfarin", "suffix": " is a commonly prescribed anticoagulant for the prevention of venous thromboembo"}, {"to": "1230", "prefix": "sm, systemic embolism, and other thromboembolic events. But, successful use of ", "from": "1223", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " has been challenged by its large inter-individual variation in required warfari"}, {"to": "1311", "prefix": "rfarin has been challenged by its large inter-individual variation in required ", "from": "1304", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose and narrow therapeutic index.(1) Doses can differ >10-fold among patients "}, {"to": "1487", "prefix": "e similar levels of anticoagulation. In attempts to explain the variability in ", "from": "1480", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose, formal pharmacogenetic techniques have been applied to try and identify p"}, {"to": "1718", "prefix": "tant. It is now well-recognized that Single Nucleotide Polymorphisms (SNPs) in ", "from": "1711", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "'s major metabolizing enzyme (cytochrome P-450 (CYP) 2C9) and its pharmacodynami"}, {"to": "1882", "prefix": "amic target (vitamin K epoxide reductase; VKORC1) have a significant impact on ", "from": "1875", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose requirement.(2–5) Multiple investigators have incorporated patients' genet"}, {"to": "2238", "prefix": "se regression models can only account for at most 55–60% of the variability in ", "from": "2231", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose.\n\nThe Biopharmaceutics Drug Disposition Classification System (BDDCS), whi"}, {"to": "3579", "prefix": " transporters has been shown for a number of other Class 2 drugs as well.(13)\n\n", "from": "3572", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "Warfarin", "suffix": " is a racemic mixture of S- and R- enatiomers with S-warfarin being 2–5 times mo"}, {"to": "3640", "prefix": "ugs as well.(13)\n\nWarfarin is a racemic mixture of S- and R- enatiomers with S-", "from": "3633", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " being 2–5 times more potent and conferring the majority of its anticoagulant ac"}, {"to": "3830", "prefix": " and R-enatiomers are eliminated almost exclusively by CYP metabolism, i.e., S-", "from": "3823", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " principally by CYP2C9 metabolism to form the primary metabolite 7-hydroxywarfar"}, {"to": "3933", "prefix": "CYP2C9 metabolism to form the primary metabolite 7-hydroxywarfarin (14, 15); R-", "from": "3926", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " principally by CYP3A4 metabolism to form 10-hydroxywarfarin.(15)\n\nSince warfari"}, {"to": "4014", "prefix": "rfarin principally by CYP3A4 metabolism to form 10-hydroxywarfarin.(15)\n\nSince ", "from": "4007", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " is classified as a BDDCS Class 2 drug(10), the potential for hepatic uptake tra"}, {"to": "4239", "prefix": " considered, a proposition not previously studied. By inhibiting the uptake of ", "from": "4232", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " into the liver, warfarin would have decreased access to its major metabolizing "}, {"to": "4264", "prefix": "n not previously studied. By inhibiting the uptake of warfarin into the liver, ", "from": "4257", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " would have decreased access to its major metabolizing CYP enzymes resulting in "}, {"to": "4454", "prefix": " on initial in vitro rat and human hepatocyte data showing decreased uptake of ", "from": "4447", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " in the presence of rifampin, a clinical trial in healthy volunteers was conduct"}, {"to": "4599", "prefix": "volunteers was conducted to examine the impact of hepatic uptake inhibition on ", "from": "4592", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics.\n\nGo to:\nRESULTS\nIn Vitro Study – Rat and Human Hepatocyte Upt"}, {"to": "4755", "prefix": "atocyte Uptake\n\nIn the presence of 100 μM rifampin, the uptake of 1 μM racemic ", "from": "4748", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " was decreased by 23% in rat hepatocytes (p < 0.05; Figure 1A) and 34% in human "}, {"to": "4945", "prefix": "Figure 1B) compared to control.\n\nFigure 1\nFigure 1\nInhibition of the uptake of ", "from": "4938", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (1μM) by rifampin (100 μM) into (a) rat and (b) human hepatocytes. Values are m"}, {"to": "5183", "prefix": " < 0.001 compared to control. ...\nClinical Study\n\nPharmacokinetics of S- and R-", "from": "5176", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "\nFigure 2 displays the concentration-time profiles of S- and R-warfarin after a "}, {"to": "5254", "prefix": "- and R-warfarin\nFigure 2 displays the concentration-time profiles of S- and R-", "from": "5247", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " after a single oral dose of 7.5 mg warfarin alone or with a single intravenous "}, {"to": "5298", "prefix": "ntration-time profiles of S- and R-warfarin after a single oral dose of 7.5 mg ", "from": "5291", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone or with a single intravenous dose of rifampin. Data from a previous study"}, {"to": "5619", "prefix": "travenous dose(11, 16). Therefore, in the current study we focused on S- and R-", "from": "5612", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " concentration-time data from 0–12 hours (Figure 2 inset) that would represent t"}, {"to": "5792", "prefix": "e period of hepatic OATP inhibition by rifampin and when any uptake effects on ", "from": "5785", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics, if any, would be seen. Rifampin had no effect on the AUC0–12h"}, {"to": "5886", "prefix": "cokinetics, if any, would be seen. Rifampin had no effect on the AUC0–12h of S-", "from": "5879", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " or R-warfarin compared to control days when warfarin was given alone (Table 1),"}, {"to": "5900", "prefix": " any, would be seen. Rifampin had no effect on the AUC0–12h of S-warfarin or R-", "from": "5893", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " compared to control days when warfarin was given alone (Table 1), as well as Cm"}, {"to": "5939", "prefix": "fect on the AUC0–12h of S-warfarin or R-warfarin compared to control days when ", "from": "5932", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " was given alone (Table 1), as well as Cmax (maximum plasma concentration) and T"}, {"to": "6178", "prefix": "single dose of intravenous rifampin on the mean plasma concentrations of (a) S-", "from": "6171", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and (b) R-warfarin in 10 healthy volunteers after a single oral dose of 7.5 mg "}, {"to": "6197", "prefix": "avenous rifampin on the mean plasma concentrations of (a) S-warfarin and (b) R-", "from": "6190", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " in 10 healthy volunteers after a single oral dose of 7.5 mg racemic warfarin. I"}, {"to": "6274", "prefix": "R-warfarin in 10 healthy volunteers after a single oral dose of 7.5 mg racemic ", "from": "6267", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ". Inset: depicts 0 to 12 h data only. Error bars show ...\nTable 1\nTable 1\nPharma"}, {"to": "6396", "prefix": "y. Error bars show ...\nTable 1\nTable 1\nPharmacokinetic parametersa of R- and S-", "from": "6389", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " in 10 healthy volunteers following a single oral dose of 7.5 mg warfarin alone "}, {"to": "6469", "prefix": "and S-warfarin in 10 healthy volunteers following a single oral dose of 7.5 mg ", "from": "6462", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone or in combination with a single dose of intravenous rifampin.\nAnalysis of"}, {"to": "6642", "prefix": "oncentration-time data showed rifampin significantly decreased the AUC0–∞ of S-", "from": "6635", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " by 15% (p < 0.04) and R-warfarin by 25% (p < 0.001) (Figure 2; Table 1). The ap"}, {"to": "6675", "prefix": "ampin significantly decreased the AUC0–∞ of S-warfarin by 15% (p < 0.04) and R-", "from": "6668", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " by 25% (p < 0.001) (Figure 2; Table 1). The apparent terminal half-life (t1/2) "}, {"to": "6768", "prefix": "% (p < 0.001) (Figure 2; Table 1). The apparent terminal half-life (t1/2) of S-", "from": "6761", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " was not significantly different on rifampin days (p = 0.13). For R-warfarin, a "}, {"to": "6844", "prefix": " S-warfarin was not significantly different on rifampin days (p = 0.13). For R-", "from": "6837", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", a 25% shortening of the terminal t1/2 was seen on rifampin days (p < 0.001). T"}, {"to": "7040", "prefix": "tribution (Vss/F) was unaffected by the presence of rifampin for both S- and R-", "from": "7033", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ".\n\nPharmacokinetics of warfarin metabolites\nThe concentration-time profiles of 7"}, {"to": "7071", "prefix": "d by the presence of rifampin for both S- and R-warfarin.\n\nPharmacokinetics of ", "from": "7064", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolites\nThe concentration-time profiles of 7-hydroxywarfarin (S-warfarin me"}, {"to": "7148", "prefix": "f warfarin metabolites\nThe concentration-time profiles of 7-hydroxywarfarin (S-", "from": "7141", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolite) and 10-hydroxywarfarin (R-warfarin metabolite) after a single oral "}, {"to": "7195", "prefix": "rofiles of 7-hydroxywarfarin (S-warfarin metabolite) and 10-hydroxywarfarin (R-", "from": "7188", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolite) after a single oral dose of 7.5 mg warfarin alone or with a single "}, {"to": "7251", "prefix": " 10-hydroxywarfarin (R-warfarin metabolite) after a single oral dose of 7.5 mg ", "from": "7244", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone or with a single intravenous dose of rifampin are shown in Figure 3. Rifa"}, {"to": "8257", "prefix": "120 hour), and therefore, a significant proportion of AUC0–∞ was extrapolated (", "from": "8250", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone, 64 +/− 11%; warfarin plus rifampin, 44% +/− 12%,). For the same reason, "}, {"to": "8285", "prefix": "significant proportion of AUC0–∞ was extrapolated (warfarin alone, 64 +/− 11%; ", "from": "8278", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " plus rifampin, 44% +/− 12%,). For the same reason, our terminal t1/2 estimate f"}, {"to": "8670", "prefix": "xywarfarin in 10 healthy volunteers after a single oral dose of 7.5 mg racemic ", "from": "8663", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ". Inset: depicts the same data on a semilogarithmic ...\nTable 2\nTable 2\nPharmaco"}, {"to": "8781", "prefix": "e data on a semilogarithmic ...\nTable 2\nTable 2\nPharmacokinetic parametersa of ", "from": "8774", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolites in 10 healthy volunteers following a single oral dose of 7.5 mg war"}, {"to": "8866", "prefix": "in metabolites in 10 healthy volunteers following a single oral dose of 7.5 mg ", "from": "8859", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone or in combination with a single dose of intravenous rifampin.\nAUC ratios "}, {"to": "9021", "prefix": "\nAUC ratios of metabolite to parent\nThe AUC0–∞ ratio of 7-hydroxywarfarin to S-", "from": "9014", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and 10-hydroxywarfarin to R-warfarin increased 20% and 58% respectively with ri"}, {"to": "9058", "prefix": "he AUC0–∞ ratio of 7-hydroxywarfarin to S-warfarin and 10-hydroxywarfarin to R-", "from": "9051", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " increased 20% and 58% respectively with rifampin treatment (p < 0.01 for both; "}, {"to": "9295", "prefix": "nt during each treatment period.\nPharmacodynamics\nA single 7.5 mg dose of oral ", "from": "9288", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " caused a small, transient increase in INR from baseline during each treatment p"}, {"to": "9544", "prefix": "0.01 for both), but rifampin caused no differences in INR measures compared to ", "from": "9537", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone (Table 4).\n\nTable 4\nTable 4\nMean pharmacodynamic parameters in 10 healthy"}, {"to": "9683", "prefix": "mic parameters in 10 healthy volunteers following a single oral dose of 7.5 mg ", "from": "9676", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone or in combination with a single dose of intravenous rifampin.\nSafety\nAll "}, {"to": "10092", "prefix": "or the disposition of the widely-used, narrow therapeutic index, anticoagulant ", "from": "10085", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ". The results of our clinical study demonstrated that co-administration of the p"}, {"to": "10306", "prefix": "e intravenous dose, had no effect on the AUC0–12h and Cmax values of S- and R- ", "from": "10299", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " or S-warfarin's hydroxyl metabolite. Accordingly, OATP uptake transport is like"}, {"to": "10320", "prefix": "dose, had no effect on the AUC0–12h and Cmax values of S- and R- warfarin or S-", "from": "10313", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "'s hydroxyl metabolite. Accordingly, OATP uptake transport is likely not clinica"}, {"to": "10447", "prefix": "P uptake transport is likely not clinically significant for the disposition of ", "from": "10440", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and will provide no further insight into mechanisms of warfarin drug-drug inter"}, {"to": "10511", "prefix": "disposition of warfarin and will provide no further insight into mechanisms of ", "from": "10504", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " drug-drug interactions or genetic variation important in warfarin dose selectio"}, {"to": "10577", "prefix": "echanisms of warfarin drug-drug interactions or genetic variation important in ", "from": "10570", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose selection.\n\nRifampin was chosen as a model OATP inhibitor to block the in "}, {"to": "10702", "prefix": "as a model OATP inhibitor to block the in vivo OATP-mediated hepatic uptake of ", "from": "10695", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "(11, 17, 18). Because of rifampin's shorter t1/2 (2.9 ±0.9 h(19)) relative to S-"}, {"to": "10798", "prefix": "18). Because of rifampin's shorter t1/2 (2.9 ±0.9 h(19)) relative to S- and R- ", "from": "10791", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (39h and 49h respectively, as determined in our clinical study) and because we "}, {"to": "11028", "prefix": " enzyme induction effect, rifampin was only present in plasma for a portion of ", "from": "11021", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "'s concentration-time curve.OATP inhibition and any potential effect on warfarin"}, {"to": "11108", "prefix": "arfarin's concentration-time curve.OATP inhibition and any potential effect on ", "from": "11101", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics occurred at most during the time of rifampin presence, and the"}, {"to": "11626", "prefix": "dy, the best parameters to capture the potential effects of OATP inhibition on ", "from": "11619", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics were the AUC0–12h and Cmax. No effect on either of these pharm"}, {"to": "11748", "prefix": " and Cmax. No effect on either of these pharmacokinetic parameters for S- or R-", "from": "11741", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " were seen in the presence of rifampin suggesting OATP transport of warfarin is "}, {"to": "11824", "prefix": " R-warfarin were seen in the presence of rifampin suggesting OATP transport of ", "from": "11817", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " is not clinically important.\n\nTwo previous clinical studies by our laboratory u"}, {"to": "12545", "prefix": " in tissues. In our current study we did not see a change in Vss/F for S- or R-", "from": "12538", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " on rifampin days (Table 1), which we would have predicted if OATP transport pro"}, {"to": "12659", "prefix": ", which we would have predicted if OATP transport processes were important for ", "from": "12652", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " distribution.\n\nIn contrast to our clinical study, our in vitro data showed that"}, {"to": "12748", "prefix": "istribution.\n\nIn contrast to our clinical study, our in vitro data showed that ", "from": "12741", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " uptake into hepatocytes was inhibited by rifampin in both rats and humans (Figu"}, {"to": "12910", "prefix": "(Figure 1) presumably via OATP uptake transporter inhibition. The magnitude of ", "from": "12903", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " uptake inhibition (23% in rat hepatocytes and 34% in human hepatocytes) was mod"}, {"to": "13632", "prefix": "ons of rifampin would result in additional OATP inhibition and therefore alter ", "from": "13625", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmcokinetics, although the clinical relevance would be questionable. The dis"}, {"to": "14156", "prefix": "ertaken to identify polymorphisms in the human genome that may be important in ", "from": "14149", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose selection. In these GWAS studies, no common variants in hepatic uptake tra"}, {"to": "14333", "prefix": "or any other drug transporters were found to be significant in determining the ", "from": "14326", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose requirements of patients.(2–5) Genetic variants of a transporter will not "}, {"to": "14700", "prefix": "uirements. This negative predictive value has now been demonstrated nicely for ", "from": "14693", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and OATP uptake transporters through the results of our clinical study and the "}, {"to": "15551", "prefix": "CYP2C9(24, 25) and CYP3A4 (25–28), the major metabolizing enzymes for S- and R-", "from": "15544", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " respectively, has been described after multiple dose rifampin. The effect of mu"}, {"to": "15663", "prefix": "escribed after multiple dose rifampin. The effect of multiple dose rifampin on ", "from": "15656", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics was highlighted in a clinical trial of four healthy men.(24) A"}, {"to": "15847", "prefix": "etreatment with 300 mg oral rifampin twice per day, a three-fold increase in R-", "from": "15840", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " clearance and a two-fold increase in S-warfarin clearance were seen. Interestin"}, {"to": "15895", "prefix": "ay, a three-fold increase in R-warfarin clearance and a two-fold increase in S-", "from": "15888", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " clearance were seen. Interestingly, our clinical study using only single dose r"}, {"to": "16012", "prefix": "ingly, our clinical study using only single dose rifampin immediately prior to ", "from": "16005", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " likely demonstrates a mild enzyme inductive effect indicated by the small but s"}, {"to": "16143", "prefix": " effect indicated by the small but significant decrease in AUC0–∞ for S- and R-", "from": "16136", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (15% decrease and 25% decrease respectively) and terminal t1/2 for R-warfarin ("}, {"to": "16221", "prefix": "-warfarin (15% decrease and 25% decrease respectively) and terminal t1/2 for R-", "from": "16214", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (25% decrease) with rifampin treatment. The increase in Cmax and AUC for the R-"}, {"to": "16309", "prefix": "(25% decrease) with rifampin treatment. The increase in Cmax and AUC for the R-", "from": "16302", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolite 10-hydroxywarfarin and the increase in the AUC ratio of 10-hydroxywa"}, {"to": "16409", "prefix": "0-hydroxywarfarin and the increase in the AUC ratio of 10-hydroxywarfarin to R-", "from": "16402", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " further supports induction of R-warfarin metabolism via CYP3A4. The pharmacokin"}, {"to": "16450", "prefix": " AUC ratio of 10-hydroxywarfarin to R-warfarin further supports induction of R-", "from": "16443", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolism via CYP3A4. The pharmacokinetics of the specific S-warfarin metaboli"}, {"to": "16521", "prefix": "on of R-warfarin metabolism via CYP3A4. The pharmacokinetics of the specific S-", "from": "16514", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolite 7-hydroxywarfarin did not change with rifampin treatment and therefo"}, {"to": "16649", "prefix": "nge with rifampin treatment and therefore is not congruent with induction of S-", "from": "16642", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolism via CYP2C9.\n\nThe pharmacokinetic effect of enzyme induction appeared"}, {"to": "16792", "prefix": "nzyme induction appeared to be delayed since early in the time course S- and R-", "from": "16785", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " concentration-time curves, AUC0–12h, and Cmax were similar with and without rif"}, {"to": "17517", "prefix": "rease in the AUC0–∞ of nifedipine.(30) Nonetheless, the potential induction of ", "from": "17510", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolism by single-dose rifampin in our study does not alter the interpretati"}, {"to": "17721", "prefix": "tudy as any induction was small (especially for the more biologically active S-", "from": "17714", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ") and it occurred late in the time-course after the primary endpoints (0–12 hour"}, {"to": "17838", "prefix": "time-course after the primary endpoints (0–12 hours).\n\nWe purposely selected a ", "from": "17831", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose for this study (7.5mg) that would provide adequate drug levels for pharmac"}, {"to": "18142", "prefix": " a previous healthy volunteer study that also used a single 7.5mg dose of oral ", "from": "18135", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ".(31) The addition of rifampin had no effect on the warfarin pharmacodynamic res"}, {"to": "18202", "prefix": "7.5mg dose of oral warfarin.(31) The addition of rifampin had no effect on the ", "from": "18195", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacodynamic response as measured by INRmax and AUC0–96h, INR (Table 3) and "}, {"to": "18517", "prefix": "s.\n\nIn conclusion, our single dose clinical study of the effect of rifampin on ", "from": "18510", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics in healthy volunteers suggeststhat hepatic uptake via OATP may"}, {"to": "19788", "prefix": "entration of rifampin was chosen to maximize OATP inhibition and any effect on ", "from": "19781", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " uptake Rifampin is a known inhibitor of the 3 major human OATPs, being a more p"}, {"to": "19995", "prefix": "han OATP2B1.(18,33) The uptake study was initiated by addition of 1 μM racemic ", "from": "19988", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (Sigma-Aldrich; St. Louis, MO). After 2 minutes of uptake, a 0.5 mL aliquot was"}, {"to": "21850", "prefix": "yburide(12). Subjects received on Day 1 of each study period either (A) 7.5 mg ", "from": "21843", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (one 7.5 mg warfarin tab; Bristol-Myers Squibb, Princeton, NJ) or (B) 7.5 mg wa"}, {"to": "21871", "prefix": " received on Day 1 of each study period either (A) 7.5 mg warfarin (one 7.5 mg ", "from": "21864", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " tab; Bristol-Myers Squibb, Princeton, NJ) or (B) 7.5 mg warfarin immediately fo"}, {"to": "21936", "prefix": "n (one 7.5 mg warfarin tab; Bristol-Myers Squibb, Princeton, NJ) or (B) 7.5 mg ", "from": "21929", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " immediately following a 30-minute intravenous infusion of 600 mg rifampin (600 "}, {"to": "22325", "prefix": "randomization. Subjects fasted starting the night before until 3 hours after a ", "from": "22318", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose, abstained from caffeinated beverages, alcoholic beverages and orange juic"}, {"to": "22464", "prefix": "ic beverages and orange juice starting the night before until 24 hours after a ", "from": "22457", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dose. Grapefruit and grapefruit juice were not allowed to be consumed from 7 da"}, {"to": "22726", "prefix": " for drug level measurements were collected at the following times relative to ", "from": "22719", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dosing: predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours. The blood sam"}, {"to": "23033", "prefix": ") were collected for INR determination at 0, 12, 24, 48, 72 and 96 hours after ", "from": "23026", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " dosing.\n\nPharmacokinetic analysis\nPharmacokinetic parameters for R- and S-warfa"}, {"to": "23116", "prefix": "arin dosing.\n\nPharmacokinetic analysis\nPharmacokinetic parameters for R- and S-", "from": "23109", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and their major metabolites were estimated from plasma concentration data via n"}, {"to": "23664", "prefix": "n's inhibitory effect on hepatic OATPs and the anticipated changes in R- and S-", "from": "23657", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetics (i.e. AUC). Given S-warfarin's much longer half-life(31, 34–41"}, {"to": "23710", "prefix": " anticipated changes in R- and S-warfarin pharmacokinetics (i.e. AUC). Given S-", "from": "23703", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "'s much longer half-life(31, 34–41) compared to rifampin(41), rifampin was expec"}, {"to": "23846", "prefix": "ifampin(41), rifampin was expected to be present in plasma for only portion of ", "from": "23839", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": "'s concentration time profile. Data from a previous study by our laboratory and "}, {"to": "24158", "prefix": "us dose.(11, 16) Accordingly, our primary outcome was the AUC0–12h of S- and R-", "from": "24151", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", which represents the time a potential inhibitory effect on hepatic OATPs by ri"}, {"to": "24852", "prefix": "procal of the first-order absorption rate (ka) constant estimated when fitting ", "from": "24845", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " data to a two-compartmental model with first-order absorption. Vss/F was calcul"}, {"to": "25451", "prefix": "ogarithmic trapezoidal method.\n\nStatistical analysis\nUsing previously reported ", "from": "25444", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " pharmacokinetic data in healthy volunteers(31), a sample size of 10 subjects wo"}, {"to": "25595", "prefix": " size of 10 subjects would provide > 80% power to detect a 30% difference in S-", "from": "25588", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " AUC0–∞ between the two treatments. Logarithmic transformation of Cmax, t1/2, Vs"}, {"to": "26089", "prefix": "etric mean ratios of the rifampin treatment values relative to control values (", "from": "26082", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " alone) and their 95% confidence intervals were calculated for all parameters. T"}, {"to": "26367", "prefix": "ally significant at p < 0.05.\n\nAnalytic Methods\nThe concentrations of S- and R-", "from": "26360", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and their main metabolites were measured using high pressure liquid chromatogra"}, {"to": "26698", "prefix": "zation mode. The multiple reaction monitor was set at 307–161 m/z for R- and S-", "from": "26691", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", 323–177 m/z for 7-hydroxy-warfarin, 323–250 m/z for 10-hydroxy-warfarin, 312–1"}, {"to": "26734", "prefix": "onitor was set at 307–161 m/z for R- and S-warfarin, 323–177 m/z for 7-hydroxy-", "from": "26727", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", 323–250 m/z for 10-hydroxy-warfarin, 312–166 m/z for d5-warfarin (internal sta"}, {"to": "26771", "prefix": "and S-warfarin, 323–177 m/z for 7-hydroxy-warfarin, 323–250 m/z for 10-hydroxy-", "from": "26764", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", 312–166 m/z for d5-warfarin (internal standard for S- and R-warfarin) and 312–"}, {"to": "26800", "prefix": "or 7-hydroxy-warfarin, 323–250 m/z for 10-hydroxy-warfarin, 312–166 m/z for d5-", "from": "26793", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (internal standard for S- and R-warfarin) and 312–117 m/z for d5-warfarin (inte"}, {"to": "26841", "prefix": "-hydroxy-warfarin, 312–166 m/z for d5-warfarin (internal standard for S- and R-", "from": "26834", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ") and 312–117 m/z for d5-warfarin (internal standard for metabolites).\n\nThe samp"}, {"to": "26874", "prefix": "r d5-warfarin (internal standard for S- and R-warfarin) and 312–117 m/z for d5-", "from": "26867", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (internal standard for metabolites).\n\nThe samples and standards for S- and R-wa"}, {"to": "26960", "prefix": "n (internal standard for metabolites).\n\nThe samples and standards for S- and R-", "from": "26953", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (Sigma-Aldrich, St. Louis, MO) were prepared by liquid-liquid extraction of 0.5"}, {"to": "27110", "prefix": "extraction of 0.5 mL plasma with 2.5 mL methyl t-butyl ether containing 1μM d5-", "from": "27103", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " as internal standard. After being vortexed for one minute, the sample was centr"}, {"to": "27438", "prefix": "hen reconstituted in acetonitrile for analysis.\n\nThe samples and standards for ", "from": "27431", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolites were prepared by liquid-liquid extraction of 100μL plasma with 500μ"}, {"to": "27558", "prefix": "uid-liquid extraction of 100μL plasma with 500μL of methanol containing 1μM d5-", "from": "27551", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " as internal standard. Samples were vortexed for one minute followed by centrifu"}, {"to": "27914", "prefix": "pernatant was collected for analysis.\n\nChromatographic conditions for S- and R-", "from": "27907", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " were as described by Naidong and colleagues(43). In brief, R-warfarin and S-war"}, {"to": "27984", "prefix": "S- and R-warfarin were as described by Naidong and colleagues(43). In brief, R-", "from": "27977", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and S-warfarin were separated isocratically on a Cyclobond™ I 2000 β-cyclodextr"}, {"to": "27999", "prefix": "in were as described by Naidong and colleagues(43). In brief, R-warfarin and S-", "from": "27992", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " were separated isocratically on a Cyclobond™ I 2000 β-cyclodextrin 250 × 4.6mm,"}, {"to": "28188", "prefix": "lobond™ I 2000 50 × 4.6, 5μm guard column (Sigma-Aldrich, St. Louis, MO). R-d5-", "from": "28181", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and S-d5-warfarin (racemic d5-warfarin from Toronto Research Chemicals, Inc., O"}, {"to": "28206", "prefix": "× 4.6, 5μm guard column (Sigma-Aldrich, St. Louis, MO). R-d5-warfarin and S-d5-", "from": "28199", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " (racemic d5-warfarin from Toronto Research Chemicals, Inc., Ontario, Canada) en"}, {"to": "28227", "prefix": "mn (Sigma-Aldrich, St. Louis, MO). R-d5-warfarin and S-d5-warfarin (racemic d5-", "from": "28220", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " from Toronto Research Chemicals, Inc., Ontario, Canada) enantiomers were also s"}, {"to": "28374", "prefix": "ntiomers were also separated by the β-cyclodextrin column and co-eluted with R-", "from": "28367", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and S-warfarin, respectively. The mobile phase consisted of acetonitrile:acetic"}, {"to": "28389", "prefix": "lso separated by the β-cyclodextrin column and co-eluted with R-warfarin and S-", "from": "28382", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ", respectively. The mobile phase consisted of acetonitrile:acetic acid:triethyla"}, {"to": "28599", "prefix": "as 1mL/min. The injection volume was 100μL. Retention times were 7.5 min for S-", "from": "28592", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " and 8.3 min for R-warfarin.\n\nChromatography for warfarin metabolites was perfor"}, {"to": "28626", "prefix": "olume was 100μL. Retention times were 7.5 min for S-warfarin and 8.3 min for R-", "from": "28619", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": ".\n\nChromatography for warfarin metabolites was performed on an Agilent Eclipse X"}, {"to": "28656", "prefix": "es were 7.5 min for S-warfarin and 8.3 min for R-warfarin.\n\nChromatography for ", "from": "28649", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " metabolites was performed on an Agilent Eclipse XDB C18 column (150 × 4.6 mm, 5"}, {"to": "29093", "prefix": " at a flow rate of 1mL/min. The run time was 10 min.\n\nThe methods for S- and R-", "from": "29086", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "PMC3091944", "exact": "warfarin", "suffix": " were validated from 1.5 to 300 ng/ml. The 1 h and 2 h samples were diluted 1-fo"}, {"to": "205", "prefix": "ce of the non-specific organic anion transporting polypeptide (OATP) inhibitor ", "from": "198", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ", a clinical study was conducted in 10 healthy volunteers. In a randomized, sing"}, {"to": "436", "prefix": "g dose of warfarin alone or immediately following a 600 mg intravenous dose of ", "from": "429", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ". Rifampin did not significantly alter R- or S- warfarin area under the concentr"}, {"to": "446", "prefix": "warfarin alone or immediately following a 600 mg intravenous dose of rifampin. ", "from": "439", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "Rifampin", "suffix": " did not significantly alter R- or S- warfarin area under the concentration-time"}, {"to": "601", "prefix": "tration-time curve (AUC) from 0–12 hours (period of hepatic OATP inhibition by ", "from": "594", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ") or Cmax (maximum plasma concentration). AUC0–∞ was decreased on rifampin days "}, {"to": "675", "prefix": "n by rifampin) or Cmax (maximum plasma concentration). AUC0–∞ was decreased on ", "from": "668", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days for both R- (25% reduction; p < 0.001) and S-warfarin (15% reduction; p < "}, {"to": "3243", "prefix": "and glyburide.(12) Using concomitant administration of single dose intravenous ", "from": "3236", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " as a non-specific OATP inhibitor, hepatic uptake inhibition resulted in a 1.3 a"}, {"to": "4482", "prefix": " human hepatocyte data showing decreased uptake of warfarin in the presence of ", "from": "4475", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ", a clinical trial in healthy volunteers was conducted to examine the impact of "}, {"to": "4718", "prefix": "TS\nIn Vitro Study – Rat and Human Hepatocyte Uptake\n\nIn the presence of 100 μM ", "from": "4711", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ", the uptake of 1 μM racemic warfarin was decreased by 23% in rat hepatocytes (p"}, {"to": "4963", "prefix": "d to control.\n\nFigure 1\nFigure 1\nInhibition of the uptake of warfarin (1μM) by ", "from": "4956", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " (100 μM) into (a) rat and (b) human hepatocytes. Values are mean ± SD (rat, n ="}, {"to": "5350", "prefix": "single oral dose of 7.5 mg warfarin alone or with a single intravenous dose of ", "from": "5343", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ". Data from a previous study by our laboratory and information provided in the p"}, {"to": "5488", "prefix": "information provided in the package insert, predict relevant concentrations of ", "from": "5481", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " for up to 12 hours after a single 600 mg intravenous dose(11, 16). Therefore, i"}, {"to": "5752", "prefix": "re 2 inset) that would represent the time period of hepatic OATP inhibition by ", "from": "5745", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " and when any uptake effects on warfarin pharmacokinetics, if any, would be seen"}, {"to": "5842", "prefix": "d when any uptake effects on warfarin pharmacokinetics, if any, would be seen. ", "from": "5835", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "Rifampin", "suffix": " had no effect on the AUC0–12h of S-warfarin or R-warfarin compared to control d"}, {"to": "6126", "prefix": " concentration).\n\nFigure 2\nFigure 2\nThe effect of a single dose of intravenous ", "from": "6119", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " on the mean plasma concentrations of (a) S-warfarin and (b) R-warfarin in 10 he"}, {"to": "6536", "prefix": "e of 7.5 mg warfarin alone or in combination with a single dose of intravenous ", "from": "6529", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ".\nAnalysis of all concentration-time data showed rifampin significantly decrease"}, {"to": "6593", "prefix": "e dose of intravenous rifampin.\nAnalysis of all concentration-time data showed ", "from": "6586", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " significantly decreased the AUC0–∞ of S-warfarin by 15% (p < 0.04) and R-warfar"}, {"to": "6812", "prefix": "ent terminal half-life (t1/2) of S-warfarin was not significantly different on ", "from": "6805", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days (p = 0.13). For R-warfarin, a 25% shortening of the terminal t1/2 was seen"}, {"to": "6904", "prefix": " (p = 0.13). For R-warfarin, a 25% shortening of the terminal t1/2 was seen on ", "from": "6897", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days (p < 0.001). The steady-state volume of distribution (Vss/F) was unaffecte"}, {"to": "7013", "prefix": " steady-state volume of distribution (Vss/F) was unaffected by the presence of ", "from": "7006", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " for both S- and R-warfarin.\n\nPharmacokinetics of warfarin metabolites\nThe conce"}, {"to": "7303", "prefix": "single oral dose of 7.5 mg warfarin alone or with a single intravenous dose of ", "from": "7296", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " are shown in Figure 3. Rifampin had no significant effect on 7-hydroxywarfarin "}, {"to": "7335", "prefix": "rin alone or with a single intravenous dose of rifampin are shown in Figure 3. ", "from": "7328", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "Rifampin", "suffix": " had no significant effect on 7-hydroxywarfarin AUC0–12h or any other its pharma"}, {"to": "7479", "prefix": "or any other its pharmacokinetic parameters (Table 2). For 10-hydroxywarfarin, ", "from": "7472", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " also had no effect on the AUC0–12h(Table 2). But, after 12 hours the concentrat"}, {"to": "7672", "prefix": "roxywarfarin between treatments began to diverge with higher concentrations on ", "from": "7665", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days (Figure 3b). The Cmax of 10-hydroxywarfarin was increased 111% on rifampin"}, {"to": "7752", "prefix": "ifampin days (Figure 3b). The Cmax of 10-hydroxywarfarin was increased 111% on ", "from": "7745", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days (p < 0.001) but no change in Tmax was seen. Rifampin treatment also result"}, {"to": "7810", "prefix": "as increased 111% on rifampin days (p < 0.001) but no change in Tmax was seen. ", "from": "7803", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "Rifampin", "suffix": " treatment also resulted in an 84% increase in the AUC0–120h (p < 0.001) and 16%"}, {"to": "7987", "prefix": "in the AUC0–∞ (p < 0.05) of 10-hydroxywarfarin. Terminal t1/2 decreased 50% on ", "from": "7980", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days (p < 0.001). Because of its extremely long terminal t1/2, a large portion "}, {"to": "8299", "prefix": "oportion of AUC0–∞ was extrapolated (warfarin alone, 64 +/− 11%; warfarin plus ", "from": "8292", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ", 44% +/− 12%,). For the same reason, our terminal t1/2 estimate for 10-hydroxyw"}, {"to": "8507", "prefix": " terminal phase.\n\nFigure 3\nFigure 3\nThe effect of a single dose of intravenous ", "from": "8500", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " on the mean plasma concentrations of (a) 7-hydroxywarfarin and (b) 10-hydroxywa"}, {"to": "8933", "prefix": "e of 7.5 mg warfarin alone or in combination with a single dose of intravenous ", "from": "8926", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ".\nAUC ratios of metabolite to parent\nThe AUC0–∞ ratio of 7-hydroxywarfarin to S-"}, {"to": "9107", "prefix": "n and 10-hydroxywarfarin to R-warfarin increased 20% and 58% respectively with ", "from": "9100", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " treatment (p < 0.01 for both; Table 3).\n\nTable 3\nTable 3\nAUC0–∞ ratios of wafar"}, {"to": "9485", "prefix": "he maximum INR (INRmax) vs. baseline INR (INRbaseline; p < 0.01 for both), but ", "from": "9478", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " caused no differences in INR measures compared to warfarin alone (Table 4).\n\nTa"}, {"to": "9750", "prefix": "e of 7.5 mg warfarin alone or in combination with a single dose of intravenous ", "from": "9743", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ".\nSafety\nAll 10 subjects who were enrolled completed the study. No significant a"}, {"to": "10201", "prefix": "linical study demonstrated that co-administration of the potent OATP inhibitor ", "from": "10194", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ", given as a single intravenous dose, had no effect on the AUC0–12h and Cmax val"}, {"to": "10603", "prefix": "-drug interactions or genetic variation important in warfarin dose selection.\n\n", "from": "10596", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "Rifampin", "suffix": " was chosen as a model OATP inhibitor to block the in vivo OATP-mediated hepatic"}, {"to": "10735", "prefix": "k the in vivo OATP-mediated hepatic uptake of warfarin(11, 17, 18). Because of ", "from": "10728", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": "'s shorter t1/2 (2.9 ±0.9 h(19)) relative to S- and R- warfarin (39h and 49h res"}, {"to": "10901", "prefix": "spectively, as determined in our clinical study) and because we could not give ", "from": "10894", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " as multiple doses dues to its metabolic enzyme induction effect, rifampin was o"}, {"to": "10975", "prefix": "give rifampin as multiple doses dues to its metabolic enzyme induction effect, ", "from": "10968", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " was only present in plasma for a portion of warfarin's concentration-time curve"}, {"to": "11170", "prefix": "ential effect on warfarin pharmacokinetics occurred at most during the time of ", "from": "11163", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " presence, and therefore, outcome measures for our study needed to be suitably s"}, {"to": "11384", "prefix": "on. Previous reports have shown that after a single 600 mg intravenous dose of ", "from": "11377", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " to healthy volunteers, rifampin was present for up to 12–24 hours in plasma. (1"}, {"to": "11416", "prefix": "that after a single 600 mg intravenous dose of rifampin to healthy volunteers, ", "from": "11409", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " was present for up to 12–24 hours in plasma. (11, 16) Assuming a similar time o"}, {"to": "11519", "prefix": " up to 12–24 hours in plasma. (11, 16) Assuming a similar time of exposure for ", "from": "11512", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " in our clinical study, the best parameters to capture the potential effects of "}, {"to": "11786", "prefix": "e pharmacokinetic parameters for S- or R-warfarin were seen in the presence of ", "from": "11779", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " suggesting OATP transport of warfarin is not clinically important.\n\nTwo previou"}, {"to": "12072", "prefix": "pharmacokinetics of atorvastatin and glyburide with hepatic OATP inhibition by ", "from": "12065", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": "(11, 12). The AUC of atorvastatin was 680% higher and the AUC of glyburide 130% "}, {"to": "12170", "prefix": "he AUC of atorvastatin was 680% higher and the AUC of glyburide 130% higher in ", "from": "12163", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " vs. control phases. In those clinical studies rifampin also produced a large de"}, {"to": "12225", "prefix": "lyburide 130% higher in rifampin vs. control phases. In those clinical studies ", "from": "12218", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " also produced a large decrease in the Vss/F for both drugs (atorvastatin, 93% d"}, {"to": "12557", "prefix": " In our current study we did not see a change in Vss/F for S- or R-warfarin on ", "from": "12550", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " days (Table 1), which we would have predicted if OATP transport processes were "}, {"to": "12798", "prefix": "ur in vitro data showed that warfarin uptake into hepatocytes was inhibited by ", "from": "12791", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " in both rats and humans (Figure 1) presumably via OATP uptake transporter inhib"}, {"to": "13026", "prefix": "t hepatocytes and 34% in human hepatocytes) was modest at the concentration of ", "from": "13019", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " (100 μM) used for the hepatocyte uptake studies. The 100 μM concentration of ri"}, {"to": "13112", "prefix": "n (100 μM) used for the hepatocyte uptake studies. The 100 μM concentration of ", "from": "13105", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " used in our hepatocyte uptake studies is significantly higher than peak plasma "}, {"to": "13300", "prefix": "ere likely achieved in our healthy volunteers after a single IV dose of 600 mg ", "from": "13293", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " (17–20μM (11, 16)) and could explain the disagreement between our in vitro and "}, {"to": "13560", "prefix": "uride. We cannot rule-out the possibility that higher plasma concentrations of ", "from": "13553", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " would result in additional OATP inhibition and therefore alter warfarin pharmco"}, {"to": "15100", "prefix": "kinetics in human clinical studies.(13, 20, 21)\n\nIntravenous administration of ", "from": "15093", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " conceivably minimized any potential confounding interactions in the intestine a"}, {"to": "15302", "prefix": "level although the lack of an interaction cannot be fully confirmed. By giving ", "from": "15295", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " as a single dose, we attempted to avoid the well-described and clinically relev"}, {"to": "15613", "prefix": "mes for S- and R-warfarin respectively, has been described after multiple dose ", "from": "15606", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ". The effect of multiple dose rifampin on warfarin pharmacokinetics was highligh"}, {"to": "15651", "prefix": ", has been described after multiple dose rifampin. The effect of multiple dose ", "from": "15644", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " on warfarin pharmacokinetics was highlighted in a clinical trial of four health"}, {"to": "15796", "prefix": "l trial of four healthy men.(24) After 3 days of pretreatment with 300 mg oral ", "from": "15789", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " twice per day, a three-fold increase in R-warfarin clearance and a two-fold inc"}, {"to": "15982", "prefix": " clearance were seen. Interestingly, our clinical study using only single dose ", "from": "15975", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " immediately prior to warfarin likely demonstrates a mild enzyme inductive effec"}, {"to": "16250", "prefix": "5% decrease respectively) and terminal t1/2 for R-warfarin (25% decrease) with ", "from": "16243", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " treatment. The increase in Cmax and AUC for the R-warfarin metabolite 10-hydrox"}, {"to": "16579", "prefix": "cs of the specific S-warfarin metabolite 7-hydroxywarfarin did not change with ", "from": "16572", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " treatment and therefore is not congruent with induction of S-warfarin metabolis"}, {"to": "16877", "prefix": "in concentration-time curves, AUC0–12h, and Cmax were similar with and without ", "from": "16870", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ". Such a delay is expected based on the mechanism of rifampin enzyme induction t"}, {"to": "16938", "prefix": " with and without rifampin. Such a delay is expected based on the mechanism of ", "from": "16931", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " enzyme induction through activation of the nuclear transcription factor pregnan"}, {"to": "17145", "prefix": "cal study examining the time-course of CYP enzyme induction with multiple-dose ", "from": "17138", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " using verapamil as a probe substrate reported a half-life of 1 day for the incr"}, {"to": "17298", "prefix": "y for the increase in CYP enzyme activity.(29) CYP induction after single dose ", "from": "17291", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " has previously been shown with a single dose of 1200 mg oral rifampin given 12 "}, {"to": "17368", "prefix": "gle dose rifampin has previously been shown with a single dose of 1200 mg oral ", "from": "17361", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " given 12 hours before oral nifedipine, resulting in a 64% decrease in the AUC0–"}, {"to": "17552", "prefix": "30) Nonetheless, the potential induction of warfarin metabolism by single-dose ", "from": "17545", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " in our study does not alter the interpretation of the primary objective of this"}, {"to": "18172", "prefix": "study that also used a single 7.5mg dose of oral warfarin.(31) The addition of ", "from": "18165", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " had no effect on the warfarin pharmacodynamic response as measured by INRmax an"}, {"to": "18505", "prefix": "rmacodynamics.\n\nIn conclusion, our single dose clinical study of the effect of ", "from": "18498", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " on warfarin pharmacokinetics in healthy volunteers suggeststhat hepatic uptake "}, {"to": "18734", "prefix": " this highly metabolized, narrow therapeutic index, anticoagulant. Single-dose ", "from": "18727", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " may induce metabolizing enzymes such as CYP2C9 and CYP3A4.\n\nGo to:\nMETHODS\nIn V"}, {"to": "19684", "prefix": "ed for 5 minute in a 37°C water bath with either control (0.1% DMSO) or 100 μM ", "from": "19677", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": ". The 100 μM concentration of rifampin was chosen to maximize OATP inhibition an"}, {"to": "19722", "prefix": "ith either control (0.1% DMSO) or 100 μM rifampin. The 100 μM concentration of ", "from": "19715", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " was chosen to maximize OATP inhibition and any effect on warfarin uptake Rifamp"}, {"to": "19804", "prefix": "ampin was chosen to maximize OATP inhibition and any effect on warfarin uptake ", "from": "19797", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "Rifampin", "suffix": " is a known inhibitor of the 3 major human OATPs, being a more potent inhibitor "}, {"to": "22010", "prefix": "5 mg warfarin immediately following a 30-minute intravenous infusion of 600 mg ", "from": "22003", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " (600 mg rifampin powder for injection reconstituted in 10 ml sterile water; Bed"}, {"to": "22027", "prefix": "ediately following a 30-minute intravenous infusion of 600 mg rifampin (600 mg ", "from": "22020", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " powder for injection reconstituted in 10 ml sterile water; Bedford Laboratories"}, {"to": "23578", "prefix": "portion of the log plasma concentration–time curve. We were most interested in ", "from": "23571", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": "'s inhibitory effect on hepatic OATPs and the anticipated changes in R- and S-wa"}, {"to": "23766", "prefix": "cs (i.e. AUC). Given S-warfarin's much longer half-life(31, 34–41) compared to ", "from": "23759", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": "(41), rifampin was expected to be present in plasma for only portion of warfarin"}, {"to": "23780", "prefix": " Given S-warfarin's much longer half-life(31, 34–41) compared to rifampin(41), ", "from": "23773", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " was expected to be present in plasma for only portion of warfarin's concentrati"}, {"to": "24020", "prefix": "tion provided in the package insert, predict relevant plasma concentrations of ", "from": "24013", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " for up to 12 hours after a single 600 mg intravenous dose.(11, 16) Accordingly,"}, {"to": "24244", "prefix": "n, which represents the time a potential inhibitory effect on hepatic OATPs by ", "from": "24237", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " would occur.\n\nAUC0–12h and AUC0–120h were found using the linear/logarithmic tr"}, {"to": "26035", "prefix": "ed as mean ± standard deviation. In addition, the geometric mean ratios of the ", "from": "26028", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC3091944", "exact": "rifampin", "suffix": " treatment values relative to control values (warfarin alone) and their 95% conf"}, {"to": "3151", "prefix": "ansporting polypeptides (OATPs) in the disposition of two BDDCS Class 2 drugs: ", "from": "3140", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3091944", "exact": "atorvastatin", "suffix": "(11) and glyburide.(12) Using concomitant administration of single dose intraven"}, {"to": "12017", "prefix": "esign as used here demonstrated significant changes in the pharmacokinetics of ", "from": "12006", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3091944", "exact": "atorvastatin", "suffix": " and glyburide with hepatic OATP inhibition by rifampin(11, 12). The AUC of ator"}, {"to": "12105", "prefix": "tin and glyburide with hepatic OATP inhibition by rifampin(11, 12). The AUC of ", "from": "12094", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3091944", "exact": "atorvastatin", "suffix": " was 680% higher and the AUC of glyburide 130% higher in rifampin vs. control ph"}, {"to": "12298", "prefix": "l studies rifampin also produced a large decrease in the Vss/F for both drugs (", "from": "12287", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3091944", "exact": "atorvastatin", "suffix": ", 93% decrease; glyburide, 60% decrease). This decrease in Vss/F likely demonstr"}, {"to": "21752", "prefix": "y to document the importance of OATP hepatic uptake in healthy voluneteers for ", "from": "21741", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3091944", "exact": "atorvastatin", "suffix": "(11) and glyburide(12). Subjects received on Day 1 of each study period either ("}, {"to": "3169", "prefix": "es (OATPs) in the disposition of two BDDCS Class 2 drugs: atorvastatin(11) and ", "from": "3161", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": ".(12) Using concomitant administration of single dose intravenous rifampin as a "}, {"to": "3356", "prefix": "nhibitor, hepatic uptake inhibition resulted in a 1.3 and 6.8 fold increase in ", "from": "3348", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": " and atorvastin exposure, respectively, as measured by the total area under the "}, {"to": "12031", "prefix": "e demonstrated significant changes in the pharmacokinetics of atorvastatin and ", "from": "12023", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": " with hepatic OATP inhibition by rifampin(11, 12). The AUC of atorvastatin was 6"}, {"to": "12146", "prefix": "on by rifampin(11, 12). The AUC of atorvastatin was 680% higher and the AUC of ", "from": "12138", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": " 130% higher in rifampin vs. control phases. In those clinical studies rifampin "}, {"to": "12323", "prefix": "uced a large decrease in the Vss/F for both drugs (atorvastatin, 93% decrease; ", "from": "12315", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": ", 60% decrease). This decrease in Vss/F likely demonstrated inhibition of uptake"}, {"to": "13478", "prefix": "sults, but the in vitro effects were similar to what we observed in vitro with ", "from": "13470", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": ". We cannot rule-out the possibility that higher plasma concentrations of rifamp"}, {"to": "21770", "prefix": "ortance of OATP hepatic uptake in healthy voluneteers for atorvastatin(11) and ", "from": "21762", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4815", "setId": "PMC3091944", "exact": "glyburide", "suffix": "(12). Subjects received on Day 1 of each study period either (A) 7.5 mg warfarin"}, {"to": "17161", "prefix": "ning the time-course of CYP enzyme induction with multiple-dose rifampin using ", "from": "17153", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11170", "setId": "PMC3091944", "exact": "verapamil", "suffix": " as a probe substrate reported a half-life of 1 day for the increase in CYP enzy"}, {"to": "17406", "prefix": "n shown with a single dose of 1200 mg oral rifampin given 12 hours before oral ", "from": "17397", "name": "Nifedipine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7417", "setId": "PMC3091944", "exact": "nifedipine", "suffix": ", resulting in a 64% decrease in the AUC0–∞ of nifedipine.(30) Nonetheless, the "}, {"to": "17463", "prefix": " 12 hours before oral nifedipine, resulting in a 64% decrease in the AUC0–∞ of ", "from": "17454", "name": "Nifedipine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7417", "setId": "PMC3091944", "exact": "nifedipine", "suffix": ".(30) Nonetheless, the potential induction of warfarin metabolism by single-dose"}, {"to": "19664", "prefix": "then pre-incubated for 5 minute in a 37°C water bath with either control (0.1% ", "from": "19661", "name": "Dimethyl Sulfoxide", "fullId": "http://purl.bioontology.org/ontology/MESH/D004121", "setId": "PMC3091944", "exact": "DMSO", "suffix": ") or 100 μM rifampin. The 100 μM concentration of rifampin was chosen to maximiz"}, {"to": "20139", "prefix": "take, a 0.5 mL aliquot was transferred to a tube containing 700 μL of silicone:", "from": "20129", "name": "Mineral Oil", "fullId": "http://purl.bioontology.org/ontology/MESH/D008899", "setId": "PMC3091944", "exact": "mineral oil", "suffix": " mixture (83.3:16.7 v/v). The tube was then centrifuged for 10 sec at 13,000 rpm"}, {"to": "27384", "prefix": "p organic layer was collected, dried under nitrogen, and then reconstituted in ", "from": "27373", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC3091944", "exact": "acetonitrile", "suffix": " for analysis.\n\nThe samples and standards for warfarin metabolites were prepared"}, {"to": "28447", "prefix": "ed with R-warfarin and S-warfarin, respectively. The mobile phase consisted of ", "from": "28436", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC3091944", "exact": "acetonitrile", "suffix": ":acetic acid:triethylamine (1000:3:2.5 v:v:v) and the flow rate was 1mL/min. The"}, {"to": "28473", "prefix": "warfarin, respectively. The mobile phase consisted of acetonitrile:acetic acid:", "from": "28461", "name": "triethylamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1307097", "setId": "PMC3091944", "exact": "triethylamine", "suffix": " (1000:3:2.5 v:v:v) and the flow rate was 1mL/min. The injection volume was 100μ"}]